VRTX logo

Vertex Pharmaceuticals Incorporated

VRTX
Healthcare|Biotechnology|US
$547.09
+4.59 (+0.85%)
DCF Value
$349.13
Tangible Book / Share
$39.31
Graham Number
$170.60
Cash / Share
$24.87

Analyst Consensus

Buy56 analysts
Strong Buy
0
Buy
48
Hold
7
Sell
1
Strong Sell
0
Consensus Target
$580.20
Implied Upside
+6.1%
Low Target
$350.00
High Target
$665.00

Price Target Trend

Last Month
$634.50
2 targets · +16% vs price
Last Quarter
$622.90
10 targets · +14% vs price
Last Year
$560.77
48 targets · +3% vs price
All Time
$470.58
112 targets · -14% vs price

Rating Trend

Dec 25
20 buy · 11 hold · 2 sell
Jan 26
23 buy · 10 hold · 2 sell
Feb 26
25 buy · 6 hold · 2 sell
Mar 26
27 buy · 5 hold · 2 sell
Apr 26
27 buy · 5 hold · 2 sell
May 26
27 buy · 5 hold · 1 sell
Jun 26
27 buy · 5 hold · 2 sell
Jul 26
27 buy · 4 hold · 2 sell
Aug 26
23 buy · 5 hold · 2 sell
Sep 26
26 buy · 4 hold · 2 sell
Oct 26
26 buy · 5 hold · 2 sell
Nov 26
26 buy · 5 hold · 2 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 3, 2026Cantor FitzgeraldCarter Gould$619.00(+16%)$535.41StreetInsider
Nov 3, 2026Wells FargoMohit Bansal$650.00(+18%)$553.15StreetInsider
Oct 8, 2026RBC Capital$576.00(+15%)$502.62TheFly
Sep 28, 2026UBS$615.00(+16%)$528.04TheFly
Sep 23, 2026JefferiesAkash Tewari$640.00(+24%)$514.99StreetInsider
Sep 22, 2026H.C. WainwrightAndrew Fein$641.00(+23%)$519.67StreetInsider
Sep 1, 2026Morgan StanleyTerence Flynn$665.00(+21%)$547.65TheFly
Sep 1, 2026Goldman Sachs$653.00(+20%)$544.52TheFly
Aug 11, 2026BernsteinJeffrey Walch$608.00(+15%)$530.29StreetInsider
Aug 10, 2026Wolfe ResearchAndy Chen$562.00(+8%)$522.78StreetInsider
Aug 5, 2026Truist Financial$565.00(+16%)$488.56TheFly
Aug 5, 2026Barclays$617.00(+29%)$478.70TheFly
Aug 4, 2026Cantor Fitzgerald$595.00(+26%)$470.72TheFly
Aug 4, 2026Canaccord Genuity$442.00(-6%)$470.72TheFly
Aug 4, 2026Stifel Nicolaus$500.00(+6%)$470.72TheFly
Jul 13, 2026UBS$585.00(+21%)$481.70TheFly
Jul 13, 2026Truist Financial$560.00(+17%)$479.01TheFly
Jul 7, 2026RBC Capital$570.00(+8%)$529.59TheFly
Jul 7, 2026Robert W. Baird$350.00(-34%)$529.59TheFly
May 27, 2026Truist FinancialDanielle Brill$542.00(+24%)$435.93StreetInsider

Recent Rating Actions

FirmActionRatingDate
BarclaysmaintainOverweightNov 4, 2026
JP MorganmaintainOverweightNov 3, 2026
Goldman SachsmaintainBuyNov 3, 2026
Morgan StanleymaintainOverweightNov 3, 2026
ScotiabankmaintainSector OutperformNov 3, 2026
UBSmaintainBuyNov 3, 2026
TD CowenmaintainBuyNov 3, 2026
Wells FargomaintainOverweightNov 3, 2026
RBC CapitalmaintainOutperformNov 3, 2026
Cantor FitzgeraldmaintainOverweightNov 3, 2026
StifelmaintainHoldNov 3, 2026
RBC CapitalmaintainOutperformOct 8, 2026
UBSmaintainBuySep 28, 2026
Truist SecuritiesmaintainBuyAug 5, 2026
BarclaysmaintainOverweightAug 5, 2026
Cantor FitzgeraldmaintainOverweightAug 4, 2026
TD CowenmaintainBuyAug 4, 2026
Canaccord GenuitymaintainHoldAug 4, 2026
UBSmaintainBuyJul 13, 2026
Truist SecuritiesmaintainBuyJul 13, 2026
BairdmaintainUnderperformJul 7, 2026
RBC CapitalmaintainOutperformJul 7, 2026
BarclaysmaintainOverweightMay 6, 2026
RBC CapitalmaintainOutperformMay 5, 2026
BernsteinmaintainOutperformMay 5, 2026

Earnings History

Next report: Feb 11, 2027 · EPS est. $4.23
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Nov 2, 2026$4.76$4.82$3.44B$3.42B
Aug 3, 2026$4.73$4.74$3.33B$3.23B
May 4, 2026$4.47$4.24$2.99B$2.99B
Feb 12, 2026$5.03$5.11$3.19B$3.18B
Nov 3, 2025$4.80$4.57$3.08B$3.06B
Aug 4, 2025$4.52$4.29$2.96B$2.91B
May 5, 2025$4.06$4.25$2.77B$2.86B
Feb 10, 2025$3.98$4.02$2.91B$2.78B

News

Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years

Vertex Pharmaceuticals' moat in cystic fibrosis remains nearly impregnable. The company's diversification efforts are slowly ramping up, and more is to come.

Nov 5, 2026fool.com
Associated Banc Corp Purchases 5,962 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Associated Banc Corp acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,962 shares of the pharmaceutical company's stock, valued at approximately $3,117,000. A number of other hedge funds

Nov 5, 2026defenseworld.net
Vertex Pharmaceuticals Incorporated $VRTX Stock Sold by AIA Group Ltd

AIA Group Ltd reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,080 shares of the pharmaceutical company's stock after selling 7,521 shares during the period. AIA Group Ltd's holdings

Nov 4, 2026defenseworld.net
Vertex Pharmaceuticals Thrives on Higher Sales and Guidance

VRTX's Q3 fiscal 2027 revenue rose 12% YoY to $3.44B, driven by cystic fibrosis and new products like CASGEVY and PALSONIFY.

Nov 4, 2026fxempire.com
Aware Super Pty Ltd as trustee of Aware Super Acquires 11,017 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Aware Super Pty Ltd as trustee of Aware Super boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 121.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,055 shares of the pharmaceutical company's stock

Nov 4, 2026defenseworld.net
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates

CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.

Nov 3, 2026zacks.com
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.

Nov 3, 2026zacks.com
Vertex Pharmaceuticals Analysts Raise Their Forecasts Following Q3 Results

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported mixed results for the third quarter on Monday.

Nov 3, 2026benzinga.com
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript

Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Executive VP & Chief Commercial Officer Charles Wagner - Executive VP, COO & CFO Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Salveen Richter - Goldma…

Nov 3, 2026seekingalpha.com
Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex Pharmaceuticals NASDAQ: VRTX reported third-quarter 2026 revenue growth of 12% year over year, supported by continued cystic fibrosis franchise growth and contributions from newer products including CASGEVY, JOURNAVX and PALSONIFY.

Nov 2, 2026marketbeat.com
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Nov 2, 2026zacks.com
Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92 per share. This compares to earnings of $4.8 per share a year ago.

Nov 2, 2026zacks.com
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Alyftrek is replacing Trikafta, and that switch is still growing Vertex's cystic fibrosis franchise. Heavy spending on new launches and the Crinetics deal kept profit from rising with sales.

Nov 2, 2026fool.com
Vertex Reports Third Quarter 2026 Financial Results

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2026, and raised its full year 2026 revenue guidance. “Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition,” said Reshma Kewalramani, M.D., Ch.

Nov 2, 2026businesswire.com
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Oct 28, 2026zacks.com
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Oct 28, 2026zacks.com
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue

Amgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.

Oct 27, 2026fool.com
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.

Oct 27, 2026zacks.com
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.

Oct 26, 2026zacks.com
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oct 26, 2026zacks.com